Kenzie L Preston

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7469689/publications.pdf

Version: 2024-02-01

45317 31976 9,519 175 53 90 citations h-index g-index papers 179 179 179 6884 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Clinical pharmacology of buprenorphine: Ceiling effects at high doses. Clinical Pharmacology and Therapeutics, 1994, 55, 569-580.	4.7	670
2	Toward a model of drug relapse: an assessment of the validity of the reinstatement procedure. Psychopharmacology, 2006, 189, 1-16.	3.1	563
3	Blockade of Effects of Smoked Marijuana by the CB1-Selective Cannabinoid Receptor Antagonist SR141716. Archives of General Psychiatry, 2001, 58, 322.	12.3	437
4	Real-Time Electronic Diary Reports of Cue Exposure and Mood in the Hours Before Cocaine and Heroin Craving and Use. Archives of General Psychiatry, 2009, 66, 88.	12.3	256
5	Abuse potential and pharmacological comparison of tramadol and morphine. Drug and Alcohol Dependence, 1991, 27, 7-17.	3.2	216
6	Incubation of Cue-Induced Cigarette Craving During Abstinence in Human Smokers. Biological Psychiatry, 2011, 69, 708-711.	1.3	199
7	Primary outcome indices in illicit drug dependence treatment research: systematic approach to selection and measurement of drug use endâ€points in clinical trials. Addiction, 2012, 107, 694-708.	3.3	184
8	The reinstatement model and relapse prevention: a clinical perspective. Psychopharmacology, 2003, 168, 31-41.	3.1	181
9	Broad beneficial effects of cocaine abstinence reinforcement among methadone patients Journal of Consulting and Clinical Psychology, 1998, 66, 811-824.	2.0	169
10	Improvement in naltrexone treatment compliance with contingency management. Drug and Alcohol Dependence, 1999, 54, 127-135.	3.2	160
11	Stress in the daily lives of cocaine and heroin users: relationship to mood, craving, relapse triggers, and cocaine use. Psychopharmacology, 2011, 218, 29-37.	3.1	150
12	Single and multiple doses of rimonabant antagonize acute effects of smoked cannabis in male cannabis users. Psychopharmacology, 2007, 194, 505-515.	3.1	144
13	Increasing opiate abstinence through voucher-based reinforcement therapy. Drug and Alcohol Dependence, 1996, 41, 157-165.	3.2	143
14	Site of Opioid Action in the Human Brain: Mu and Kappa Agonists' Subjective and Cerebral Blood Flow Effects. American Journal of Psychiatry, 1998, 155, 470-473.	7.2	137
15	Cognitive-behavioral therapy plus contingency management for cocaine use: Findings during treatment and across 12-month follow-up Psychology of Addictive Behaviors, 2003, 17, 73-82.	2.1	134
16	Randomized trial of buprenorphine for treatment of concurrent opiate and cocaine dependence. Clinical Pharmacology and Therapeutics, 2004, 75, 34-48.	4.7	133
17	Methadone Dose Increase and Abstinence Reinforcement for Treatment of Continued Heroin Use During Methadone Maintenance. Archives of General Psychiatry, 2000, 57, 395.	12.3	126
18	Sex differences in cocaine/heroin users: Drug-use triggers and craving in daily life. Drug and Alcohol Dependence, 2013, 132, 29-37.	3.2	122

#	Article	IF	Citations
19	Effects of buprenorphine and methadone in methadone-maintained subjects. Psychopharmacology, 1995, 119, 268-276.	3.1	118
20	Abuse liability, behavioral pharmacology, and physical-dependence potential of opioids in humans and laboratory animals: Lessons from tramadol. Biological Psychology, 2006, 73, 90-99.	2.2	117
21	Real-time tracking of neighborhood surroundings and mood in urban drug misusers: Application of a new method to study behavior in its geographical context. Drug and Alcohol Dependence, 2014, 134, 22-29.	3.2	113
22	Pathological Gambling Among Cocaine-Dependent Outpatients. American Journal of Psychiatry, 2000, 157, 1127-1133.	7.2	107
23	Cocaine use early in treatment predicts outcome in a behavioral treatment program Journal of Consulting and Clinical Psychology, 1998, 66, 691-696.	2.0	105
24	Tobacco, cocaine, and heroin: Craving and use during daily life. Addictive Behaviors, 2010, 35, 318-324.	3.0	105
25	Discriminative stimulus and subjective effects of theobromine and caffeine in humans. Psychopharmacology, 1994, 115, 1-8.	3.1	103
26	Cocaine craving and use during daily life. Psychopharmacology, 2009, 207, 291-301.	3.1	103
27	Assessment of cocaine use with quantitative urinalysis and estimation of new uses. Addiction, 1997, 92, 717-727.	3.3	94
28	Absorption rate of methylxanthines following capsules, cola and chocolate. European Journal of Clinical Pharmacology, 1996, 51, 319-325.	1.9	90
29	Marriage and relationship closeness as predictors of cocaine and heroin use. Addictive Behaviors, 2009, 34, 258-263.	3.0	90
30	Abuse liability studies of opioid agonist-antagonists in humans. Drug and Alcohol Dependence, 1991, 28, 49-82.	3.2	84
31	Long-term effects of repeated methylamphetamine administration on monoamine neurons in the rhesus monkey brain. Brain Research, 1985, 338, 243-248.	2.2	83
32	Heroin and cocaine craving and use during treatment: Measurement validation and potential relationships. Journal of Substance Abuse Treatment, 2006, 31, 355-364.	2.8	83
33	Buprenorphine and naloxone alone and in combination in opioid-dependent humans. Psychopharmacology, 1988, 94, 484-490.	3.1	81
34	Fluoxetine Alters the Effects of Intravenous Cocaine in Humans. Journal of Clinical Psychopharmacology, 1994, 14, 396???407.	1.4	81
35	Does cannabis use predict poor outcome for heroin-dependent patients on maintenance treatment? Past findings and more evidence against. Addiction, 2003, 98, 269-279.	3.3	81
36	Clonidine Maintenance Prolongs Opioid Abstinence and Decouples Stress From Craving in Daily Life: A Randomized Controlled Trial With Ecological Momentary Assessment. American Journal of Psychiatry, 2015, 172, 760-767.	7.2	80

#	Article	IF	CITATIONS
37	Naltrexone shortened opioid detoxification with buprenorphine. Drug and Alcohol Dependence, 1999, 56, 181-190.	3.2	77
38	Clonidine blocks stress-induced craving in cocaine users. Psychopharmacology, 2011, 218, 83-88.	3.1	72
39	Urinary Elimination of Cocaine Metabolites in Chronic Cocaine Users during Cessation. Journal of Analytical Toxicology, 2002, 26, 393-400.	2.8	71
40	Diazepam and methadone interactions in methadone maintenance. Clinical Pharmacology and Therapeutics, 1984, 36, 534-541.	4.7	70
41	Exacerbated Craving in the Presence of Stress and Drug Cues in Drug-Dependent Patients. Neuropsychopharmacology, 2018, 43, 859-867.	5.4	69
42	Effects of sublingually given naloxone in opioid-dependent human volunteers. Drug and Alcohol Dependence, 1990, 25, 27-34.	3.2	68
43	Stress, craving and mood as predictors of early dropout from opioid agonist therapy. Drug and Alcohol Dependence, 2019, 202, 200-208.	3.2	68
44	Psychostimulant addiction treatment. Neuropharmacology, 2014, 87, 150-160.	4.1	67
45	Phencyclidine-induced stereotyped behavior in monkeys: Antagonism by pimozide. European Journal of Pharmacology, 1978, 52, 379-384.	3.5	64
46	The cannabinoid CB1 receptor antagonist rimonabant attenuates the hypotensive effect of smoked marijuana in male smokers. American Heart Journal, 2006, 151, 754.e1-754.e5.	2.7	64
47	Tailored, Interactive Text Messages for Enhancing Weight Loss Among African American Adults: The TRIMM Randomized Controlled Trial. American Journal of Medicine, 2015, 128, 896-904.	1.5	64
48	Opioid detoxification with buprenorphine, clonidine, or methadone in hospitalized heroin-dependent patients with HIV infection. Drug and Alcohol Dependence, 2003, 69, 263-272.	3.2	61
49	Monitoring Cocaine Use in Substance-Abuse-Treatment Patients by Sweat and Urine Testing. Journal of Analytical Toxicology, 1999, 23, 313-322.	2.8	60
50	Combining ecological momentary assessment with objective, ambulatory measures of behavior and physiology in substance-use research. Addictive Behaviors, 2018, 83, 5-17.	3.0	59
51	Promoting abstinence from cocaine and heroin with a methadone dose increase and a novel contingency. Drug and Alcohol Dependence, 2009, 101, 92-100.	3.2	58
52	Discriminative stimulus and subjective effects of opioids with mu and kappa activity: data from laboratory animals and human subjects. Psychopharmacology, 1997, 130, 14-27.	3.1	57
53	Daily life hour by hour, with and without cocaine: an ecological momentary assessment study. Psychopharmacology, 2010, 211, 223-232.	3.1	56
54	Shaping cocaine abstinence by successive approximation Journal of Consulting and Clinical Psychology, 2001, 69, 643-654.	2.0	55

#	Article	IF	CITATIONS
55	Brain Mu-Opioid Receptor Binding Predicts Treatment Outcome in Cocaine-Abusing Outpatients. Biological Psychiatry, 2010, 68, 697-703.	1.3	54
56	Uncertainties in the geographic context of health behaviors: a study of substance users' exposure to psychosocial stress using GPS data. International Journal of Geographical Information Science, 2019, 33, 1176-1195.	4.8	54
57	Before and after: craving, mood, and background stress in the hours surrounding drug use and stressful events in patients with opioid-use disorder. Psychopharmacology, 2018, 235, 2713-2723.	3.1	52
58	The effects of buprenorphine in buprenorphine-maintained volunteers. Psychopharmacology, 1997, 129, 329-338.	3.1	51
59	Buprenorphine alone and in combination with naloxone in non-dependent humans. Drug and Alcohol Dependence, 1992, 30, 263-274.	3.2	50
60	Comparison of intravenously administered methadone, morphine and heroin. Drug and Alcohol Dependence, 1986, 17, 301-310.	3.2	49
61	Are we there yet?. , 2014, 2014, 479-488.		49
62	Measures of outcome for stimulant trials: ACTTION recommendations and research agenda. Drug and Alcohol Dependence, 2016, 158, 1-7.	3.2	49
63	Context and craving during stressful events in the daily lives of drug-dependent patients. Psychopharmacology, 2017, 234, 2631-2642.	3.1	49
64	Abstinence reinforcement maintenance contingency and one-year follow-up. Drug and Alcohol Dependence, 2002, 67, 125-137.	3.2	47
65	Changes in HIV risk behaviors among patients receiving combined pharmacological and behavioral interventions for heroin and cocaine dependence. Addictive Behaviors, 2006, 31, 868-879.	3.0	46
66	Continuous in-the-field measurement of heart rate: Correlates of drug use, craving, stress, and mood in polydrug users. Drug and Alcohol Dependence, 2015, 151, 159-166.	3.2	46
67	Sex differences in daily life stress and craving in opioid-dependent patients. American Journal of Drug and Alcohol Abuse, 2018, 44, 512-523.	2.1	45
68	The brief abstinence test: voucher-based reinforcement of cocaine abstinence. Drug and Alcohol Dependence, 2000, 58, 205-212.	3.2	44
69	Effects of High-Dose Intravenous Buprenorphine in Experienced Opioid Abusers. Journal of Clinical Psychopharmacology, 2004, 24, 479-487.	1.4	43
70	Menstrual cycle length during methadone maintenance. Addiction, 2005, 100, 829-836.	3.3	43
71	Self-report of illicit benzodiazepine use on the Addiction Severity Index predicts treatment outcome. Drug and Alcohol Dependence, 2008, 97, 150-157.	3.2	42
72	Some of the people, some of the time: field evidence for associations and dissociations between stress and drug use. Psychopharmacology, 2015, 232, 3529-3537.	3.1	40

#	Article	IF	CITATIONS
73	Prediction of stress and drug craving ninety minutes in the future with passively collected GPS data. Npj Digital Medicine, 2020, 3, 26.	10.9	40
74	Diazepam and methadone blood levels following concurrent administration of diazepam and methadone. Drug and Alcohol Dependence, 1986, 18, 195-202.	3.2	39
75	Opioid challenge evaluation of blockade by extended-release naltrexone in opioid-abusing adults: Dose–effects and time-course. Drug and Alcohol Dependence, 2012, 123, 57-65.	3.2	39
76	Intravenous buprenorphine and norbuprenorphine pharmacokinetics in humans. Drug and Alcohol Dependence, 2013, 131, 258-262.	3.2	39
77	Evaluation of mixtures of morphine and d-amphetamine for subjective and physiological effects. Drug and Alcohol Dependence, 1986, 17, 1-13.	3.2	38
78	Determination of total and free concentrations of the enantiomers of methadone and its metabolite (2-ethylidene-1,5-dimethyl-3,3-diphenyl-pyrrolidine) in human plasma by enantioselective liquid chromatography with mass spectrometric detection. Journal of Chromatography A, 2005, 1073, 237-248.	3.7	38
79	Discrimination of butorphanol and nalbuphine in opioid-dependent humans. Pharmacology Biochemistry and Behavior, 1990, 37, 511-522.	2.9	35
80	Psychoactivity and abuse potential of sumatriptan. Clinical Pharmacology and Therapeutics, 1992, 52, 635-642.	4.7	35
81	Methadone and Metabolite Urine Concentrations in Patients Maintained on Methadone. Journal of Analytical Toxicology, 2003, 27, 332-341.	2.8	34
82	Quantitative determination of the enantiomers of methadone and its metabolite (EDDP) in human saliva by enantioselective liquid chromatography with mass spectrometric detection. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2003, 796, 355-370.	2.3	33
83	Influence of psychotherapy attendance on buprenorphine treatment outcome. Journal of Substance Abuse Treatment, 2005, 28, 247-254.	2.8	33
84	Pharmacological Advances in Addiction Treatment. Substance Use and Misuse, 1985, 20, 845-867.	0.6	32
85	Spiritual/Religious Experiences and In-Treatment Outcome in an Inner-City Program for Heroin and Cocaine Dependence. Journal of Psychoactive Drugs, 2007, 39, 41-49.	1.7	32
86	End-of-day reports of daily hassles and stress in men and women with opioid-use disorder: Relationship to momentary reports of opioid and cocaine use and stress. Drug and Alcohol Dependence, 2018, 193, 21-28.	3.2	31
87	Craving and opioid use disorder: A scoping review. Drug and Alcohol Dependence, 2019, 205, 107639.	3.2	31
88	No evidence for reduction of opioid-withdrawal symptoms by cannabis smoking during a methadone dose taper. American Journal on Addictions, 2015, 24, 323-328.	1.4	30
89	Shaping cocaine abstinence by successive approximation Journal of Consulting and Clinical Psychology, 2001, 69, 643-654.	2.0	29
90	Drug discrimination methods in human drug abuse liability evaluation. Addiction, 1991, 86, 1587-1594.	3.3	28

#	Article	IF	Citations
91	Randomized trial of prize-based reinforcement density for simultaneous abstinence from cocaine and heroin Journal of Consulting and Clinical Psychology, 2007, 75, 765-774.	2.0	28
92	A Focus-Group Study on Spirituality and Substance-User Treatment. Substance Use and Misuse, 2010, 45, 134-153.	1.4	28
93	A dose response study of cognitive behavioral therapy in cocaine abusers. Journal of Substance Abuse Treatment, 2002, 23, 191-197.	2.8	27
94	Hepatitis C and human immunodeficiency virus risk behaviors in polydrug users on methadone maintenance. Journal of Substance Abuse Treatment, 2008, 35, 78-86.	2.8	27
95	Family history influence on drug abuse severity and treatment outcome. Drug and Alcohol Dependence, 2001, 61, 261-270.	3.2	26
96	Buprenorphine Reduces Cerebral Glucose Metabolism in Polydrug Abusers. Neuropsychopharmacology, 1994, 10, 157-170.	5.4	25
97	Real-time assessment of alcohol drinking and drug use in opioid-dependent polydrug users. Behavioural Pharmacology, 2016, 27, 579-584.	1.7	25
98	Sleep reductions associated with illicit opioid use and clinic-hour changes during opioid agonist treatment for opioid dependence: Measurement by electronic diary and actigraphy. Journal of Substance Abuse Treatment, 2019, 106, 43-57.	2.8	25
99	Identifying Drug (Cocaine) Intake Events from Acute Physiological Response in the Presence of Free-living Physical Activity., 2014, 2014, 71-82.		25
100	Cardiac Complications of Unwitting Co-injection of Quinine/Quinidine with Heroin in an Intravenous Drug User. Journal of General Internal Medicine, 2012, 27, 1722-1725.	2.6	24
101	Toxicologic Aspects of Heroin Substitution Treatment. Therapeutic Drug Monitoring, 2002, 24, 193-198.	2.0	23
102	Contingency management reduces injection-related HIV risk behaviors in heroin and cocaine using outpatients. Addictive Behaviors, 2008, 33, 593-604.	3.0	23
103	Evaluation of tilidine for morphine-like subjective effects and euphoria. Drug and Alcohol Dependence, 1986, 18, 273-292.	3.2	22
104	TGI Monday?: Drugâ€Dependent Outpatients Report Lower Stress and More Happiness at Work than Elsewhere. American Journal on Addictions, 2012, 21, 189-198.	1.4	22
105	RANDOMIZED TRIAL COMPARING TWO TREATMENT STRATEGIES USING PRIZEâ€BASED REINFORCEMENT OF ABSTINENCE IN COCAINE AND OPIATE USERS. Journal of Applied Behavior Analysis, 2008, 41, 551-563.	2.7	21
106	Using ecological momentary assessment to examine the relationship between craving and affect with opioid use in a clinical trial of clonidine as an adjunct medication to buprenorphine treatment. American Journal of Drug and Alcohol Abuse, 2018, 44, 502-511.	2.1	21
107	Self-administration of clonidine, oxazepam, and hydromorphone by patients undergoing methadone detoxification. Clinical Pharmacology and Therapeutics, 1985, 38, 219-227.	4.7	20
108	Assessment of dezocine for morphine-like subjective effects and miosis. Clinical Pharmacology and Therapeutics, 1985, 38, 544-548.	4.7	20

#	Article	IF	CITATIONS
109	Electrocardiographic Effects of Lofexidine and Methadone Coadministration: Secondary Findings from a Safety Study. Pharmacotherapy, 2009, 29, 495-502.	2.6	20
110	Assessment of agonist and antagonist effects of tramadol in opioid-dependent humans Experimental and Clinical Psychopharmacology, 2006, 14, 109-120.	1.8	18
111	EFFECT OF REINFORCEMENT PROBABILITY AND PRIZE SIZE ON COCAINE AND HEROIN ABSTINENCE IN PRIZEâ€BASED CONTINGENCY MANAGEMENT. Journal of Applied Behavior Analysis, 2008, 41, 539-549.	2.7	18
112	Opioid antagonist effects of dezocine in opioid-dependent humans*. Clinical Pharmacology and Therapeutics, 1996, 60, 206-217.	4.7	17
113	Occurrence of Cocaine in Urine of Substance-Abuse Treatment Patients. Journal of Analytical Toxicology, 1998, 22, 580-586.	2.8	17
114	Cyclazocine: comparison to hydromorphone and interaction with cocaine. Behavioural Pharmacology, 2004, 15, 91-102.	1.7	17
115	Daily temporal patterns of heroin and cocaine use and craving: Relationship with business hours regardless of actual employment status. Addictive Behaviors, 2013, 38, 2485-2491.	3.0	17
116	Smartphone Delivery of Mobile HIV Risk Reduction Education. AIDS Research and Treatment, 2013, 2013, 1-9.	0.7	17
117	Replication of the pharmacogenetic effect of rs678849 on buprenorphine efficacy in African–Americans with opioidÂuse disorder. Pharmacogenomics Journal, 2019, 19, 260-268.	2.0	17
118	Beyond abstinence and relapse II: momentary relationships between stress, craving, and lapse within clusters of patients with similar patterns of drug use. Psychopharmacology, 2021, 238, 1513-1529.	3.1	17
119	Open-label pilot study of bupropion plus bromocriptine for treatment of cocaine dependence. American Journal of Drug and Alcohol Abuse, 2002, 28, 189-196.	2.1	16
120	Nonreporting of cannabis use: Predictors and relationship to treatment outcome in methadone maintained patients. Addictive Behaviors, 2007, 32, 938-949.	3.0	16
121	Psychosocial functioning and cocaine use during treatment: Strength of relationship depends on type of urine-testing method. Drug and Alcohol Dependence, 2007, 91, 169-177.	3.2	16
122	Beyond abstinence and relapse: cluster analysis of drug-use patterns during treatment as an outcome measure for clinical trials. Psychopharmacology, 2020, 237, 3369-3381.	3.1	16
123	The aversive stimulus properties of repeated infusions of cocaine. Pharmacology Biochemistry and Behavior, 1981, 15, 71-74.	2.9	15
124	Rapid liquid–liquid extraction of cocaine from urine for gas chromatographic–mass spectrometric analysis. Biomedical Applications, 1997, 692, 61-65.	1.7	15
125	Supersensitivity to Naloxone following acute morphine pretreatment in humans: behavioral, hormonal and physiological effects. Drug and Alcohol Dependence, 1992, 30, 13-26.	3.2	14
126	Methamphetamine, physostigmine, atropine and mecamylamine: Effects on force lever performance. Pharmacology Biochemistry and Behavior, 1985, 23, 781-788.	2.9	13

#	Article	IF	CITATIONS
127	Methadone Treatment Induces Attenuation of Cerebrovascular Deficits Associated with the Prolonged Abuse of Cocaine and Heroin. Neuropsychopharmacology, 2003, 28, 562-568.	5.4	13
128	Cigarette smoking and short-term addiction treatment outcome. Drug and Alcohol Dependence, 2011, 115, 161-166.	3.2	13
129	Cognitiveâ€behavioural therapy for heroin and cocaine use: Ecological momentary assessment of homework simplification and compliance. Psychology and Psychotherapy: Theory, Research and Practice, 2016, 89, 276-293.	2.5	13
130	Assessment of pioglitazone and proinflammatory cytokines during buprenorphine taper in patients with opioid use disorder. Psychopharmacology, 2018, 235, 2957-2966.	3.1	13
131	Towards detecting cocaine use using smartwatches in the NIDA clinical trials network: Design, rationale, and methodology. Contemporary Clinical Trials Communications, 2019, 15, 100392.	1.1	13
132	Psychopharmacology and abuse potential of transnasal butorphanol. Drug and Alcohol Dependence, 1994, 35, 159-167.	3.2	12
133	Hemodynamic and Cognitive Effects of Lofexidine and Methadone Coadministration: A Pilot Study. Pharmacotherapy, 2007, 27, 1111-1119.	2.6	12
134	Craving mediates the association between momentary pain and illicit opioid use during treatment for opioidâ€use disorder: an ecological momentary assessment study. Addiction, 2021, 116, 1794-1804.	3.3	12
135	QT interval increased after single dose of lofexidine. BMJ: British Medical Journal, 2004, 329, 1075.	2.3	11
136	Adverse events among patients in a behavioral treatment trial for heroin and cocaine dependence: Effects of age, race, and gender. Drug and Alcohol Dependence, 2005, 80, 45-51.	3.2	11
137	Automation in an addiction treatment research clinic: Computerised contingency management, ecological momentary assessment and a protocol workflow system. Drug and Alcohol Review, 2009, 28, 3-11.	2.1	11
138	A randomized investigation of methadone doses at or over 100mg/day, combined with contingency management. Drug and Alcohol Dependence, 2013, 130, 77-84.	3.2	11
139	Substance use and hepatitis C: An ecological momentary assessment study Health Psychology, 2014, 33, 710-719.	1.6	11
140	The chippers, the quitters, and the highly symptomatic: A 12-month longitudinal study of DSM-5 opioidand cocaine-use problems in a community sample. Addictive Behaviors, 2019, 96, 183-191.	3.0	11
141	Low-dose oral cocaine in humans: acquisition of discrimination and time-course of effects. Behavioural Pharmacology, 1999, 10, 531-542.	1.7	10
142	Clonidine Increases the Likelihood That Abstinence Can Withstand Unstructured Time in Buprenorphine-maintained Outpatients. Journal of Addiction Medicine, 2017, 11, 454-460.	2.6	10
143	Conditioned gustatory avoidance induced by three cholinergic agents. Pharmacology Biochemistry and Behavior, 1981, 15, 827-828.	2.9	9
144	Cocaine effects on digital blood flow and diffusing capacity for carbon monoxide among chronic cocaine users. American Journal of Medicine, 1997, 102, 232-238.	1.5	9

#	Article	IF	CITATIONS
145	Safety and Efficacy of Bupropion Combined With Bromocriptine for Treatment of Cocaine Dependence. American Journal on Addictions, 1996, 5, 69-75.	1.4	8
146	Evaluation of the abuse potential of the novel analgesic flupirtine maleate. Drug and Alcohol Dependence, 1991, 27, 101-113.	3.2	7
147	A laboratory study of hydromorphone and cyclazocine on smoking behavior in residential polydrug users. Pharmacology Biochemistry and Behavior, 2004, 77, 711-715.	2.9	7
148	PGIS: Electronic diary data integration with GPS data initial application in substance-abuse patients. , 2010, , .		7
149	Drug abstinence effects: opioids. Addiction, 1991, 86, 1641-1646.	3.3	6
150	Do noncontingent vouchers increase drug use?. Experimental and Clinical Psychopharmacology, 2003, 11, 195-201.	1.8	6
151	Longitudinal patterns of momentary stress during outpatient opioid agonist treatment: A growth-mixture-model approach to classifying patients. Drug and Alcohol Dependence, 2021, 226, 108884.	3.2	6
152	mDebugger: Assessing and Diagnosing the Fidelity and Yield of Mobile Sensor Data., 2017,, 121-143.		6
153	Cannabis use and treatment outcome in methadone maintenance. Addiction, 2003, 98, 1321-1322.	3.3	5
154	A comparison of the central and peripheral effects of atropine on force lever performance. Pharmacology Biochemistry and Behavior, 1982, 16, 423-427.	2.9	4
155	The influence of an instruction on the stimulus effects of drugs in humans Experimental and Clinical Psychopharmacology, 1998, 6, 427-432.	1.8	4
156	Trajectories of craving during medication-assisted treatment for opioid-use disorder: Subtyping for early identification of higher risk. Drug and Alcohol Dependence, 2022, 233, 109362.	3.2	4
157	A model for pharmacological researchâ€"treatment of cocaine dependence. Journal of Substance Abuse Treatment, 1995, 12, 415-421.	2.8	3
158	Computerized Contingency Management for Motivating Behavior Change: Automated Tracking and Dynamic Reward Reinforcement Management. Proceedings of the IEEE Symposium on Computer-Based Medical Systems, 2007, , .	0.0	3
159	Defining and Predicting Opioid and Cocaine Treatment Response. Substance Use and Misuse, 2019, 54, 2134-2143.	1.4	3
160	Reward Responsiveness in Patients with Opioid Use Disorder on Opioid Agonist Treatment: Role of Comorbid Chronic Pain. Pain Medicine, 2021, 22, 2019-2027.	1.9	3
161	An Examination of the Feasibility of Detecting Cocaine Use Using Smartwatches. Frontiers in Psychiatry, 2021, 12, 674691.	2.6	3
162	I feel good? Anhedonia might not mean "without pleasure―for people treated for opioid use disorder Journal of Abnormal Psychology, 2021, 130, 537-549.	1.9	3

#	ARTICLE	IF	CITATIONS
163	Buprenorphine in Maintenance Therapy. , 2013, , 139-162.		3
164	A high-level specification for adaptive ecological momentary assessment: real-time assessment of drug craving, use and abstinence. AMIA Annual Symposium proceedings, 2005, , 455-9.	0.2	3
165	Being at work improves stress, craving, and mood for people with opioid use disorder: Ecological momentary assessment during a randomized trial of experimental employment in a contingency-management-based therapeutic workplace. Behaviour Research and Therapy, 2022, 152, 104071.	3.1	3
166	Quality of life during a randomized trial of a therapeutic-workplace intervention for opioid use disorder: Web-based mobile assessments reveal effects of drug abstinence and access to paid work. , 2021, 1, 100011.		3
167	Intra-individual variability and stability of affect and craving among individuals receiving medication treatment for opioid use disorder. Neuropsychopharmacology, 2022, 47, 1836-1843.	5.4	3
168	Buprenorphine for human immunovirus-positive opiate-dependent patients. Biological Psychiatry, 1995, 38, 135-136.	1.3	2
169	Gender Differences in Indices of Opioid Dependency and Medical Comorbidity in a Population of Hospitalized HIV-Infected African-Americans. American Journal on Addictions, 2004, 13, 281-291.	1.4	2
170	Addiction and emotion: Theories, assessment techniques, and treatment implications , 2010, , 259-280.		2
171	Effects of methamphetamine on atropine-induced conditioned gustatory avoidance. Pharmacology Biochemistry and Behavior, 1984, 20, 601-607.	2.9	1
172	5-HT3 receptor antagonism and psychoactivity. Journal of Psychopharmacology, 1996, 10, 182-187.	4.0	0
173	Bridging the information gap: assimilating preclinical and clinical findings. Psychopharmacology, 1997, 130, 1-1.	3.1	0
174	Exploring the Relationship Between Substance Use and Allostatic Load in a Treatment/Research Cohort and in a US Probability Sample (NHANES 2009–2016). Frontiers in Psychiatry, 2021, 12, 630195.	2.6	0
175	Assessment of cocaine use with quantitative urinalysis and estimation of new uses. Addiction, 1997, 92, 717-728.	3.3	O